Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Hoffman

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Thrombosis Research|July 1, 2004
Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulationAaron Lubetsky, Ron Hoffman, Reuven Zimlichman, et al.
American Journal of Hematology|July 15, 2017
Clinical significance of prothrombin G20210A mutation in homozygous patientsAmit Shemesh, Ron Hoffman, Yona Nadir, et al.
Thrombosis and Haemostasis|July 17, 2015
A novel mutation of antithrombin deficiency in six family siblings and the clinical combatYona Nadir, Ron Hoffman, Javier Corral, et al.
Annals of Hematology|March 7, 2015
Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nursesYona Nadir, Gleb Saharov, Ron Hoffman, et al.
Haematologica|November 4, 2005
Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptorYona Nadir, Tamar Katz, Galit Sarig, et al.
The Israel Medical Association Journal : IMAJ|July 8, 2019
Non-ST-Elevation Myocardial Infarction with Non-significant Coronary Artery Disease as a Symptom of Occult or New MalignancyOfer M Kobo, Elit Vainer Evgrafov, Yuval Cohen, et al.
European Journal of Haematology|August 3, 2023
Effects of anti-Xa activity monitoring on the outcome of high-risk pregnancies treated with a prophylactic dose of low-molecular-weight heparinLea Liat Nasich, Ron Hoffman, Anat Keren-Politansky, et al.
British Journal of Haematology|June 7, 2014
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutationElizabeth Hexner, Gail Roboz, Ron Hoffman, et al.
Blood|October 24, 2002
Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipientsDana G Wolf, Nell S Lurain, Tsila Zuckerman, et al.
Clinical Toxicology (Philadelphia, Pa.)|June 9, 2023
An outbreak of severe coagulopathy in northern Israel among users of illicit synthetic cannabinoids adulterated with brodifacoumYael Lurie, Yona Nadir, Ron Hoffman, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Thrombosis Research|July 1, 2004
Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulationAaron Lubetsky, Ron Hoffman, Reuven Zimlichman, et al.
American Journal of Hematology|July 15, 2017
Clinical significance of prothrombin G20210A mutation in homozygous patientsAmit Shemesh, Ron Hoffman, Yona Nadir, et al.
Thrombosis and Haemostasis|July 17, 2015
A novel mutation of antithrombin deficiency in six family siblings and the clinical combatYona Nadir, Ron Hoffman, Javier Corral, et al.
Annals of Hematology|March 7, 2015
Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nursesYona Nadir, Gleb Saharov, Ron Hoffman, et al.
Haematologica|November 4, 2005
Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptorYona Nadir, Tamar Katz, Galit Sarig, et al.
The Israel Medical Association Journal : IMAJ|July 8, 2019
Non-ST-Elevation Myocardial Infarction with Non-significant Coronary Artery Disease as a Symptom of Occult or New MalignancyOfer M Kobo, Elit Vainer Evgrafov, Yuval Cohen, et al.
European Journal of Haematology|August 3, 2023
Effects of anti-Xa activity monitoring on the outcome of high-risk pregnancies treated with a prophylactic dose of low-molecular-weight heparinLea Liat Nasich, Ron Hoffman, Anat Keren-Politansky, et al.
British Journal of Haematology|June 7, 2014
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutationElizabeth Hexner, Gail Roboz, Ron Hoffman, et al.
Blood|October 24, 2002
Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipientsDana G Wolf, Nell S Lurain, Tsila Zuckerman, et al.
Clinical Toxicology (Philadelphia, Pa.)|June 9, 2023
An outbreak of severe coagulopathy in northern Israel among users of illicit synthetic cannabinoids adulterated with brodifacoumYael Lurie, Yona Nadir, Ron Hoffman, et al.
Pageof 5